Bladder cancer is the fourth most common cancer in men and the eighth in women in both incidences and mortality and over 90% of bladder tumors are transitional cell carcinomas (TCCs). The existence of two distinct groups of tumors with different clinical features is a remarkable feature of TCC. More than 70% are in fact low-grade (LG) non-infiltrating (NI) cancers at diagnosis, that can be treated endoscopically by transurethral resection (TUR) alone, recur at least once and 10-20% progress in stage and grade. Thus repetitive and costly follow-up based on urine cytology, cystoscopy and imaging studies of the urinary tract is required, even if the prognosis is usually good. On the other hand, about 20% of tumors show muscle invasion (IN) at diagnosis and have a poor prognosis with <50% survival after 5 years [
1]. A model for at least two major pathways has emerged based on the existence of these two distinct groups of lesions [
2,
3]. LG NI tumors are generally characterized by constitutive activation of the receptor tyrosine kinase–Ras pathway, and they have activating mutations in the proto-oncogene
FGFR3[
4,
5]; in contrast, inactivating mutations of the tumor suppressor pathways of
TP53,
RB1 or
PTEN were found in muscle-invasive lesions [
5,
6]. Array comparative genomic hybridization (aCGH) studies have been instrumental in delineating genomic regions that are targeted by copy number changes, called Copy Number Alterations (CNAs). Several aCGH studies of bladder cancer have been published to date and provide the identification of a number of genomic regions of DNA amplification that contain known or candidate oncogenes including cyclin D1 (
CCND1) on 11q13 [
7,
8],
ERBB2 on 17q21 [
9],
MDM2 on 12q14–q15 [
10], and
E2F3 on 6p22 [
11]. Similarly, deletions of genomic regions containing tumor suppressor genes, such as
CDKN2A,
DBC1 and
TSC1 (at 9p21, 9q33 and 9q34, respectively),
PTEN on 10q23,
RB1 on 13q14, and
TP53 on 17p13 [
12]. Some of these aberrations have been associated with the pathological stage and/or outcome of bladder cancer. Several studies evidenced exclusive genomic alterations in LG and HG tumors [
13], with a significant increase in CNAs and genomic instability with increasing stage/grade and with outcome [
14,
15]. In addition, the over-representation of focal amplifications, such as at chromosome 6p22, was significantly associated with HG IN tumors [
16] and recurrent cases [
17].
Since it is currently believed that bladder cancer is derived from a common cancer stem cell (CSC) likely derived by transformation of urothelial cells of the basal layer, bladder CSCs have been isolated based on basal cell markers such as CD44. Nevertheless, in this way, CSCs have only been identified in HG IN tumors [
18‐
21] suggesting that a distinct progenitor cell type exists for LG NI. A recent study of Dancik et al. provides evidence of the existence of distinct progenitor cells in NI and IN tumors, supporting new conceptual framework for investigating and understanding bladder cancer [
22]. CSCs are responsible for treatment failure and cancer recurrence since they exhibit specific stem cells features, such as growth as nonadherent spheres in a stem cell medium, unlimited self-renewal, multipotency and lineage-specific differentiation [
23]. Understanding the origins and supporting mechanisms of these cells and their relation to the bulk population has a great relevance for improving the knowledge of cancer pathogenesis and therapeutics [
23].
In the first step of this study we performed conventional chromosome analysis on TCC biopsies with different histotypes (LG vs HG) in order to detect rough differences between them. We subsequently performed aCGH analysis on another set of 20 biopsies to look for chromosomal imbalances and smaller differences. In a second step, we compared the global pattern of CNAs in 16 of these biopsies with the corresponding isolated CSCs in order to reveal specific genomic aberrations that would provide them with growth advantages and a more aggressive phenotype.